SCHEMBL3924964

SCHEMBL3924964

Cc1cc2c(s1)S(=O)(=O)N(C)C(=O)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15919040 0.74 GRIA1 (0.33)
SCHEMBL3919487 0.73 MEN1 (0.32)
SCHEMBL11481318 0.71 DRD1 (0.36)
SCHEMBL8344705 0.70 CA2 (0.38)
SCHEMBL11477363 0.66 CA2 (0.33)
SCHEMBL5565090 0.66 BRD4 (0.31)
SCHEMBL3917904 0.63 GAA (0.34)
SCHEMBL4611133 0.63 CA9 (0.50)
SCHEMBL3919989 0.62 MEN1 (0.42)
SCHEMBL3920183 0.60 CA9 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534787-B2 Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-19 US disclosed
US-20090099159-A1 Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-16 US disclosed
US-7393843-B2 Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-01 US disclosed
US-20080139541-A1 Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds BORNEMANN KLAUS 2008-06-12 US disclosed
US-7375220-B2 Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2008-05-20 US disclosed
EP-1750719-A2 TREATMENT OF DISEASES ASSOCIATED WITH ALTERED LEVEL OF AMYLOID BETA PEPTIDES Boehringer Ingelheim International GmbH (DE) 2007-02-14 EP disclosed
US-20060040928-A1 Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2006-02-23 US disclosed
US-20050277635-A1 Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-12-15 US disclosed
WO-2005110422-A2 TREATMENT OF DISEASES ASSOCIATED WITH ALTERED LEVEL OF AMYLOID BETA PEPTIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 WO disclosed